A Study of LY2969822 in Healthy Participants | NCT02018887

ID	Type	Description	Link
I4W-FW-HMJD	Other Identifier	Eli Lilly and Company

A Study of LY2969822 in Healthy Participants | NCT02018887 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
LY2969822 (Part A)	Experimental	Single dose of LY2969822 administered orally in 2 of 3 study periods.	Drug: LY2969822
Placebo (Part A)	Placebo Comparator	Single dose of placebo administered orally in 1 of 3 study periods.	Drug: Placebo
LY2969822 (Part B)	Experimental	LY2969822 administered orally for 14 days.	Drug: LY2969822
Placebo (Part B)	Placebo Comparator	Placebo administered orally for 14 days.	Drug: Placebo
LY2969822 (Part C)	Experimental	LY2969822 administered orally for 14 days.	Drug: LY2969822
Placebo (Part C)	Placebo Comparator	Placebo administered orally for 14 days.

Name	Type	Description	Arm Group Labels	Other Names
LY2969822	Drug	Capsules administered orally	LY2969822 (Part A) LY2969822 (Part B) LY2969822 (Part C)

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration	A summary of other nonserious adverse events (AEs) and all SAEs, regardless of causality, is located in the Reported Adverse Events section.	Baseline Through End of Study (up to Week 7)

Secondary Outcomes

Measure	Description	Time Frame
Pharmacokinetics (PK): Maximum Plasma Concentration (Plasma Cmax) of Prodrug LY2969822 and Active Metabolite LSN2934747	Pharmacokinetics (PK): Maximum Plasma Concentration (Plasma Cmax) of Prodrug LY2969822 and Active Metabolite LSN2934747	All Cohorts: Day 1 - 0 Hours (H), 0.5 H, 1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H; Cohort 3: Day 10 - 0 H, 0.5 H, 1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H; Cohorts 3 - 8: Day 14 - 0 H, 0.5 H,1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H

Contacts/Locations Module

Name	Affiliation	Role
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)	Eli Lilly and Company	Study Director

Locations

Facility	Status	City	State	ZIP	Country	Contacts
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.		Singapore		117597

Arm/Group Information

ID	Title	Description
FG000	Part A: Cohort 1	Participants were randomised to receive 2 single, oral doses of LY2969822 and 1 oral dose of placebo over the 3 study periods in a crossover fashion. For each study period, it was intended that 6 subjects would receive LY2969822 and 3 subjects would receive placebo. Placebo administered once, orally (PO) at all three periods. 2 milligrams (mg) LY2969822 administered once, PO during period 1. 20 mg LY2969822 administered once, PO during period 2. 40 mg LY2969822 administered once, PO during period 3.
FG001	Part A: Cohort 2	Participants were randomised to receive 2 single, oral doses of LY2969822 and 1 oral dose of placebo over the 3 study periods in a crossover fashion. For each study period, it was intended that 6 subjects would receive LY2969822 and 3 subjects would receive placebo. Placebo administered once, PO at all three periods. 6 mg LY2969822 administered once, PO during period 1. 60 mg LY2969822 administered once, PO during period 2. 20 mg LY2969822 administered once, PO during period 3.
FG002	Cohorts 3-7 - Placebo	Placebo administered once a day (QD) or twice a day (BID), PO, for 14 days.
FG003	Cohort 3 - 20 mg LY2969822 QD	20 mg LY2969822 administered QD, PO, for 14 days.
FG004	Cohort 4 - 40 mg LY2969822 QD Titrated	Up to 40 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 3 days, 20 mg QD for 2 days, and 40 mg QD for 9 days.
FG005	Cohort 5 - 80 mg LY2969822 QD Titrated	Up to 80 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 2 days, 20 mg QD for 2 days, 40 mg QD for 2 days and 80 mg QD for 8 days.
FG006	Cohort 6 - 80 mg LY2969822 BID Titrated	Up to 80 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, 40 mg BID for 2 days, and 80 mg BID for 6 days.
FG007	Cohort 7 - 40 mg LY2969822 BID Rapidly Titrated	Up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 10 mg BID for 1 day, 20 mg BID for 1 day, and 40 mg BID for 12 days.
FG008	Cohort 8 - Placebo BID	Placebo administered BID, PO, for 14 days.
FG009	Cohort 8A - 40 mg LY2969822 BID Titrated	Up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, and 40 mg BID for 8 days.)
FG010	Cohort 8B - 20 mg LY2969822 BID Titrated	Up to 20 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, and 20 mg BID for 10 days.

Periods

Title

Milestones

Reasons Not Completed

Part A: Cohorts 1-2: Period 1

Type	Comment	Milestone Data
STARTED		FG0009 subjects FG0019 subjects FG0020 subjectsPlacebo was not administered in this period. FG0030 subjectsThis dose was not administered in this period. FG004
Received One Dose of Study Drug		FG0009 subjects FG0019 subjects FG0020 subjects FG0030 subjects FG004
COMPLETED		FG0009 subjects FG0019 subjects FG0020 subjects FG0030 subjects FG004
NOT COMPLETED		FG0000 subjects FG0010 subjects FG0020 subjects FG0030 subjects FG004

Part A: Cohorts 1-2: Period 2

Type	Comment	Milestone Data
STARTED		FG0009 subjects FG0019 subjects FG0020 subjectsPlacebo was not administered in this period. FG003

Part A: Cohorts 1-2: Period 3

Type	Comment	Milestone Data
STARTED		FG0009 subjects FG0019 subjects FG0020 subjectsPlacebo was not administered in this period. FG003

Part B: Cohorts 3-7 Overall

Type	Comment	Milestone Data
STARTED		FG0000 subjectsColumn for Part A data only. FG0010 subjectsColumn for Part A data only. FG00215 subjects FG003

Part C: Cohort 8 Overall

Type	Comment	Milestone Data
STARTED		FG0000 subjects FG0010 subjects FG0020 subjectsPlacebo was not administered in this period. FG003

Baseline Characteristics Module

Arm/Group Information

ID	Title	Description
BG000	Part A: Cohorts 1-2	Part A Single Ascending Dose (SAD): Cohort 1 received placebo, 2 mg, 20 mg, or 40 mg LY2969822 PO, once, in each of 3 study periods. Cohort 2 received placebo, 6 mg, 60 mg, or 20 mg LY2969822 PO, once, in each of 3 study periods. At least 5 days elapsed between doses of study drug.
BG001

Units	Counts
Participants	BG000

Title	Description	Population Description	Parameter Type	Dispersion Type	Unit of Measure	Calculate Percentage	Denominator Units Selected	Denominators	Classes
Age, Continuous			Mean

Outcome Measures Module

Outcome Measures

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of other nonserious adverse events (AEs) and all SAEs, regardless of causality, is located in the Reported Adverse Events section.

All participants who received at least one dose of study drug.

Posted

Number

participants

Baseline Through End of Study (up to Week 7)

ID	Title	Description
OG000	Cohort 1 - Placebo	Placebo administered once, PO.
OG001	Cohort 1 - 2 mg LY2969822	20 mg LY2969822 administered once, PO.

Adverse Events Module

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Part A: Placebo	Placebo administered once, PO.

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Palpitations	Cardiac disorders	MedDRA 16.0	Systematic Assessment

More Info Module

Certain Agreements

Title	Organization	Phone	Extension	Email
Chief Medical Officer	Eli Lilly and Company	800-545-5979		ClinicalTrials.gov@lilly.com

Type	Comment	Reasons
Adverse Event		FG0000 subjects FG0010 subjects FG0020 subjects FG0030 subjects FG0040 subjects FG0050 subjects FG0060 subjects FG0070 subjects FG0081 subjects FG0093 subjects FG0100 subjects
Physician Decision		FG0000 subjects FG0010 subjects FG0020 subjects FG0030 subjects FG004

Title

Denominators

Categories

Part A

Title	Measurements
	BG00035.1± 9.5 BG001NA± NAPart A:Cohorts 1-2 data only. BG002NA± NAPart A:Cohorts 1-2 data only. BG003NA± NAPart A:Cohorts 1-2 data only. BG004NA± NAPart A:Cohorts 1-2 data only. BG005NA± NAPart A:Cohorts 1-2 data only. BG006NA± NAPart A:Cohorts 1-2 data only. BG007NA± NAPart A:Cohorts 1-2 data only. BG00835.1± 9.5

Part B

Title	Measurements
	BG000NA± NAPart B: Cohorts 3-7 data only. BG00132.6± 7.6 BG00232.7± 7.4 BG003

Part C

Title	Measurements
	BG000NA± NAPart C: Cohort 8 data only. BG001NA± NAPart C: Cohort 8 data only. BG002NA± NAPart C: Cohort 8 data only. BG003

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG0000 BG0010 BG0020 BG0030 BG0040 BG0050 BG0060 BG0070 BG0080
Not Hispanic or Latino	BG00018 BG00115 BG0029 BG0039 BG004
Unknown or Not Reported	BG0000 BG0010 BG0020 BG0030 BG004

Race (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG0000 BG0010 BG0020 BG0030 BG0040 BG0050 BG0060 BG0070 BG0080
Asian	BG00018 BG00114 BG0029 BG0038 BG004
Native Hawaiian or Other Pacific Islander	BG0000 BG0010 BG0020 BG0030 BG004
Black or African American	BG0000 BG0010 BG0020 BG0030 BG004
White	BG0000 BG0011 BG0020 BG0031 BG004
More than one race	BG0000 BG0010 BG0020 BG0030 BG004
Unknown or Not Reported	BG0000 BG0010 BG0020 BG0030 BG004

Secondary

Pharmacokinetics (PK): Maximum Plasma Concentration (Plasma Cmax) of Prodrug LY2969822 and Active Metabolite LSN2934747

All participants who received at least one dose of LY2969822 and had evaluable plasma values.

Posted

Geometric Mean

Geometric Coefficient of Variation

nanomoles per liter (nmol/L)

All Cohorts: Day 1 - 0 Hours (H), 0.5 H, 1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H; Cohort 3: Day 10 - 0 H, 0.5 H, 1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H; Cohorts 3 - 8: Day 14 - 0 H, 0.5 H,1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H

ID	Title	Description
OG000	Cohort 1 - 2 mg LY2969822	2 mg LY2969822 administered once, PO.
OG001	Cohort 1 - 20 mg LY2969822	20 mg LY2969822 administered once, PO.
OG002	Cohort 1 - 40 mg LY2969822	40 mg LY2969822 administered once, PO.
OG003	Cohort 2 - 6 mg LY2969822	6 mg LY2969822 administered once, PO.
OG004	Cohort 2 - 60 mg LY2969822	60 mg LY2969822 administered once, PO.
OG005	Cohort 2 - 20 mg LY2969822	20 mg LY2969822 administered once, PO.
OG006	Cohort 3 - 20 mg LY2969822 QD Day 1 (Fasted)	20 mg LY2969822 administered QD, PO, for 14 days.
OG007	Cohort 3 - 20 mg LY2969822 QD Day 14 (Fasted)	20 mg LY2969822 administered QD, PO, for 14 days.
OG008	Cohort 3 - 20 mg LY2969822 QD Day 10 (Fed)	20 mg LY2969822 administered QD, PO, for 14 days.
OG009	Cohort 4 - 6 mg LY2969822 QD Day 1	6 mg up to 40 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 3 days, 20 mg QD for 2 days, and 40 mg QD for 9 days.
OG010	Cohort 4 - 40 mg LY2969822 QD Day 14	6 mg up to 40 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 3 days, 20 mg QD for 2 days, and 40 mg QD for 9 days.
OG011	Cohort 5 - 6 mg LY2969822 QD Day 1	6 mg up to 80 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 2 days, 20 mg QD for 2 days, 40 mg QD for 2 days and 80 mg QD for 8 days.
OG012	Cohort 5 - 80 mg LY2969822 QD Day 14	6 mg up to 80 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 2 days, 20 mg QD for 2 days, 40 mg QD for 2 days and 80 mg QD for 8 days.
OG013	Cohort 6 - 6 mg LY2969822 BID Day 1	6 mg up to 80 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, 40 mg BID for 2 days, and 80 mg BID for 6 days.
OG014	Cohort 6 - 80 mg LY2969822 BID Day 14	6 mg up to 80 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, 40 mg BID for 2 days, and 80 mg BID for 6 days.
OG015	Cohort 7 - 10 mg LY2969822 BID Day 1	10 mg up to 40 mg LY2969822 administered QD, PO, for 14 days. Titration: 10 mg BID for 1 day, 20 mg BID for 1 day, and 40 mg BID for 12 days.
OG016	Cohort 7 - 40 mg LY2969822 BID Day 14	10 mg up to 40 mg LY2969822 administered QD, PO, for 14 days. Titration: 10 mg BID for 1 day, 20 mg BID for 1 day, and 40 mg BID for 12 days.
OG017	Cohort 8A - 6 mg LY2969822 BID Day 1	6 mg up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, and 40 mg BID for 8 days.
OG018	Cohort 8A - 40 mg BID LY2969822 Day 14	6 mg up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, and 40 mg BID for 8 days.
OG019	Cohort 8B - 6 mg LY2969822 BID Day 1	6 mg up to 20 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 10 days.
OG020	Cohort 8B - 20 mg BID LY2969822 Day 14	6 mg up to 20 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 10 days.

Units	Counts
Participants	OG0006 OG0016 OG0025 OG003

Title

Denominators

Categories

LY2969822

Title	Measurements
	OG00019.9± 28 OG001209± 20 OG002346± 21 OG003

Secondary

PK: Maximum Cerebrospinal Fluid Concentrations (CSF Cmax) of Prodrug LY2969822 and Active Metabolite LSN2934747

CSF samples were only collected in Cohort 8. All participants in Cohort 8 who received at least one dose of LY2969822 and had evaluable CSF values on Day 14.

Posted

Geometric Mean

Geometric Coefficient of Variation

nmol/L

Cohort 8: Day 14 - 0 H, 0.5 H,1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H

ID	Title	Description
OG000	Cohort 8A - 40 mg BID LY2969822 Day 14	6 mg up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, and 40 mg BID for 8 days.
OG001	Cohort 8B - 20 mg BID LY2969822 Day 14	6 mg up to 20 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 10 days.

Units	Counts
Participants	OG0001 OG0016

Title

Denominators

Categories

LY2969822

Title	Measurements
	OG000NA± NAn=1. Individual value is 9.86 nmol/L. OG0018.42± 106

LSN2934747

Title	Measurements
	OG000

Secondary

PK: Area Under the Drug Plasma Concentration Time Curve (Plasma AUC) of Prodrug LY2969822 and Active Metabolite LSN2934747

For Cohorts 1-2, AUC is extrapolated from time zero to infinity (AUC[0-inf]). For Cohorts 3 - 8, AUC is reported during one dosing interval (AUC[tau]). AUC(tau) is 24 hours for Cohorts 3 - 5 and 12 hours for Cohorts 6 - 8.

All participants who received at least one dose of LY2969822 and had evaluable plasma values.

Posted

Geometric Mean

Geometric Coefficient of Variation

nanomoles x hours per liter (nmol∙h/L)

ID	Title	Description
OG000	Cohort 1 - 2 mg LY2969822	2 mg LY2969822 administered once, PO.
OG001	Cohort 1 - 20 mg LY2969822	20 mg LY2969822 administered once, PO.
OG002	Cohort 1 - 40 mg LY2969822	40 mg LY2969822 administered once, PO.
OG003	Cohort 2 - 6 mg LY2969822	6 mg LY2969822 administered once, PO.
OG004	Cohort 2 - 60 mg LY2969822	60 mg LY2969822 administered once, PO.
OG005	Cohort 2 - 20 mg LY2969822	20 mg LY2969822 administered once, PO.
OG006	Cohort 3 - 20 mg LY2969822 QD Day 1 (Fasted)	20 mg LY2969822 administered QD, PO, for 14 days.
OG007	Cohort 3 - 20 mg LY2969822 QD Day 14 (Fasted)	20 mg LY2969822 administered QD, PO, for 14 days.
OG008	Cohort 3 - 20 mg LY2969822 QD Day 10 (Fed)	20 mg LY2969822 administered QD, PO, for 14 days.
OG009	Cohort 4 - 6 mg LY2969822 QD Day 1	6 mg up to 40 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 3 days, 20 mg QD for 2 days, and 40 mg QD for 9 days.
OG010	Cohort 4 - 40 mg LY2969822 QD Day 14	6 mg up to 40 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 3 days, 20 mg QD for 2 days, and 40 mg QD for 9 days.
OG011	Cohort 5 - 6 mg LY2969822 QD Day 1	6 mg up to 80 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 2 days, 20 mg QD for 2 days, 40 mg QD for 2 days and 80 mg QD for 8 days.
OG012	Cohort 5 - 80 mg LY2969822 QD Day 14	6 mg up to 80 mg LY2969822 administered QD, PO, for 14 days. Titration: 6 mg QD for 2 days, 20 mg QD for 2 days, 40 mg QD for 2 days and 80 mg QD for 8 days.
OG013	Cohort 6 - 6 mg LY2969822 BID Day 1	6 mg up to 80 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, 40 mg BID for 2 days, and 80 mg BID for 6 days.
OG014	Cohort 6 - 80 mg LY2969822 BID Day 14	6 mg up to 80 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, 40 mg BID for 2 days, and 80 mg BID for 6 days.
OG015	Cohort 7 - 10 mg LY2969822 BID Day 1	10 mg up to 40 mg LY2969822 administered QD, PO, for 14 days. Titration: 10 mg BID for 1 day, 20 mg BID for 1 day, and 40 mg BID for 12 days.
OG016	Cohort 7 - 40 mg LY2969822 BID Day 14	10 mg up to 40 mg LY2969822 administered QD, PO, for 14 days. Titration: 10 mg BID for 1 day, 20 mg BID for 1 day, and 40 mg BID for 12 days.
OG017	Cohort 8A - 6 mg LY2969822 BID Day 1	6 mg up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, and 40 mg BID for 8 days.
OG018	Cohort 8A - 40 mg BID LY2969822 Day 14	6 mg up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, and 40 mg BID for 8 days.
OG019	Cohort 8B - 6 mg BID Day 1	6 mg up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, and 40 mg BID for 8 days.
OG020	Cohort 8B - 20 mg BID Day 14	6 mg up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, and 40 mg BID for 8 days.

Units	Counts
Participants	OG0006 OG0016 OG0025 OG003

Title

Denominators

Categories

LY2969822

Title	Measurements
	OG00088.5± 22 OG001843± 19 OG0021730± 12 OG003

Secondary

PK: CSF AUC(Tau) of Prodrug LY2969822 and Active Metabolite LSN2934747

AUC(tau) is 12 hours.

CSF samples were only collected in Cohort 8. All participants in Cohort 8 who received at least one dose of LY2969822 and had evaluable CSF values on Day 14.

Posted

Geometric Mean

Geometric Coefficient of Variation

nmol∙h/L

Cohort 8: Day 14 - 0 H, 0.5 H,1 H, 2 H, 3 H, 4 H, 6 H, 9 H, 12 H, 16 H

ID	Title	Description
OG000	Cohort 8A - 40 mg BID LY2969822 Day 14	6 mg up to 40 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 2 days, and 40 mg BID for 8 days.
OG001	Cohort 8B - 20 mg BID LY2969822 Day 14	6 mg up to 20 mg LY2969822 administered BID, PO, for 14 days. Titration: 6 mg BID for 2 days, 10 mg BID for 2 days, 20 mg BID for 10 days.

Units	Counts
Participants	OG0001 OG0016

Title

Denominators

Categories

LY2969822

Title	Measurements
	OG000NA± NAn=1. Individual value is 1840 nmol∙h/L. OG00175.1± 85

LSN2934747

Title	Measurements
	OG000

LSN2934747

Title	Measurements
	OG000108± 21 OG001978± 10 OG0021700± 19 OG003289± 43 OG0042850± 18 OG005840± 20 OG006847± 30 OG0071200± 18 OG0081520± 14 OG009232± 35 OG0101600± 20 OG011332± 31 OG0124190± 28 OG013303± 35 OG0144130± 14 OG015461± 50 OG0162390± 17 OG017381± 21 OG018NA± NAn=1. Individual value is 2777.08 nmol/L. OG019263± 29 OG0201150± 14

LSN2934747

Title	Measurements
	OG000805± 18 OG0017030± 12 OG00213500± 25 OG0032090± 39 OG00423600± 17 OG0056970± 22 OG0065830± 36 OG0078220± 15 OG0088660± 12 OG0091710± 28 OG01010600± 28 OG0112100± 26 OG01229000± 30 OG0131810± 30 OG01425300± 18 OG0153010± 49 OG01614400± 19 OG0172670± 20 OG018NA± NAn=1. Individual value is 15800 nmol∙h/L. OG0191790± 20 OG0206920± 18